Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity... (available at www.vical . This pr...)

Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans

Date:12/11/2008

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the results of the company's Vaxfectin(R)-formulated H5N1 influenza DNA vaccine Phase 1 clinical trial and the results of nonclinical mouse studies of Vaxfectin(R)-formulated influenza vaccines produced by the company's RapidResponse(TM) manufacturing system. Risks and uncertainties include whether Vical or others will continue development of the H5N1 pandemic influenza vaccines or the RapidResponse(TM) DNA vaccine platform; whether H5N1 influenza DNA vaccine Phase 1 clinical trial results will be confirmed in larger studies; whether nonclinical results from mouse studies will advance to human clinical testing, and if so, whether such testing will yield similar results; whether the company will receive all of the NIH grant funding; whether DNA vaccines against H5N1 influenza or any other targets will be successfully developed and commercialized; whether Vical or its collaborative partners will seek or gain approval to market the influenza vaccine or any other product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; whether Vical or others will secure funding to advance the pandemic influenza DNA vaccine program; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update th
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
2. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
5. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
6. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
7. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
8. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
11. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial

Post Your Comments:

Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity...(available at www.vical . This pr...),Health